Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Article in The Lancet Oncology (March 2024)
The most recent citing publications are shown below. View all 249 publications that cite this research output on Dimensions.
Article in The Lancet Oncology (March 2024)
Article in Leukemia Research (February 2024)
Book chapter (January 2024)